NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Medanta Q2 FY27 வலுவான முடிவுகள்: வருவாய் 34% உயர்வு, ₹1,469 கோடி; PAT 38% உயர்வு, ₹219.1 கோடி
Global Health Limited (Medanta) தனது Q2 FY27 வருவாய் அழைப்பின் டிரான்ஸ்கிரிப்டை வெளியிட்டது; இது வலுவான செயல்பாட்டுச் செயல்திறனைக் காட்டுகிறது. ஒருங்கிணைந்த செயல்பாட்டு வருவாய் 34% YoY உயர்ந்து ₹1,469 கோடியாக உள்ளது. ஆப்பரேட்டிங் EBITDA 60% YoY உயர்ந்து ₹370.1 கோடியாக ஆனது; லாப வரம்பு 25.2% ஆக விரிவடைந்தது. Profit after tax 38% YoY உயர்ந்து ₹219.1 கோடியை எட்டியது; நிகர பண உபரி ₹781.5 கோடியாக உள்ளது. காஜியாபாத்தில் 2.61 ஏக்கர் நிலப் பகுதியை கையகப்படுத்தியதாகவும், 500 படுக்கைகள் கொண்ட புதிய மருத்துவமனைக்காக இதைப் பயன்படுத்தப் போவதாகவும் நிறுவனம் அறிவித்தது. இது 6 கிரீன்ஃபீல்ட் மருத்துவமனைகள் கொண்ட விரிவாக்கத் திட்டத்தின் ஒரு பகுதி.
உச்சம் நம்பிக்கை
என்ன மாறியதுMedanta தனது Q2 FY27 வருவாய் அழைப்பின் விரிவான டிரான்ஸ்கிரிப்டை வெளியிட்டது; இதன் மூலம் நொய்டா பிரிவில் EBITDA பிரேக்ஈவன் மற்றும் 500 படுக்கைகள் கொண்ட மருத்துவமனைக்காக காஜியாபாத்தில் நில கையகப்படுத்தல் உறுதி செய்யப்பட்டது.
ஏன் இது முக்கியம்EBITDA லாப வரம்பு 25.2% ஆக உயர்ந்திருப்பது வலுவான செயல்பாட்டு லீவரேஜைக் காட்டுகிறது; 6 கிரீன்ஃபீல்ட் வசதிகள் மூலம் நீண்டகால படுக்கை சேர்ப்பு குறித்த தெளிவும் உறுதிப்படுகிறது.
Q2 FY27 செயல்பாட்டு வருவாய்: INR 14,690 மில்லியன்ஆப்பரேட்டிங் EBITDA வளர்ச்சி (YoY): 60%Q2 FY27 ஆப்பரேட்டிங் EBITDA மார்ஜின்: 25.2%Q2 FY27 PAT: INR 2,191 மில்லியன்நிகர பண உபரி (நிலவரப்படி செப்டம்பர் 30, 2026): INR 7,815 மில்லியன்திட்டமிட்ட காஜியாபாத் மருத்துவமனை திறன்: 500 படுக்கைகள்
📅 குறுகிய காலம்இந்த டிரான்ஸ்கிரிப்ட் ஏற்கனவே வெளியிடப்பட்ட Q2 முடிவுகளை உறுதிப்படுத்துகிறது; நொய்டாவில் விரைவான பிரேக்ஈவன் மற்றும் ஆரோக்கியமான லாப வரம்பு உயர்வு ஆகியவை உணர்வை ஆதரிக்கின்றன.
📈 நீண்ட காலம்நீண்டகால திட்டம் 6 கிரீன்ஃபீல்ட் திட்டங்கள் மூலம் படுக்கை திறனை இருமடங்காக்குவதைச் சார்ந்துள்ளது; நீடித்த கெஸ்டேஷன் காலங்கள் இல்லாமல் விரைவான ramp-up நடந்தால்தான் உயர் ROCE-ஐத் தக்கவைக்க முடியும்.
⚠ அபாய எச்சரிக்கைகள்
6 கிரீன்ஃபீல்ட் மருத்துவமனை திட்டங்களில் செயல்படுத்தல் மற்றும் கேபெக்ஸ் செலவு அதிகரிப்பு
செயல்பாட்டு பிரேக்ஈவனுக்கு முன் புதிய வசதிகளால் ஏற்படும் கெஸ்டேஷன் தாக்கம்
👀 கவனிக்க வேண்டியவை
6 கிரீன்ஃபீல்ட் மருத்துவமனை திட்டங்களின் (காஜியாபாத் மற்றும் குவாஹாட்டி உட்பட) செயல்படுத்தும் கால அட்டவணை மற்றும் கேபெக்ஸ் செலவுகளைக் கண்காணியுங்கள்; பிரேக்ஈவனை எட்டிய நொய்டா மருத்துவமனையின் ஆக்கிரமிப்பு மற்றும் லாப வரம்பு நிலைத்தன்மையையும் கவனியுங்கள்.
Medanta Q2 FY27: Revenue Up 34% to ₹1,469 Cr, Operating EBITDA Surges 60% with Noida Breakeven
Global Health Limited (Medanta) reported strong Q2 FY27 operational and financial results, with revenue from operations growing 33.6% YoY to ₹1,469.0 crore (INR 14,690 million). Operating EBITDA jumped 60.2% YoY to ₹370.1 crore, expanding margins by 418 bps to 25.2%. Profit After Tax rose 38.3% YoY to ₹219.1 crore, supported by volume expansion and the newly launched Noida facility achieving EBITDA breakeven (₹8.6 crore EBITDA on ₹105.9 crore revenue). Total census bed capacity expanded 17.2% YoY to 3,115 beds, with occupancy reaching 66.5%.
உச்சம் நம்பிக்கை
என்ன மாறியதுGlobal Health released its Q2 & H1 FY27 investor presentation highlighting 34% topline growth and turning EBITDA positive at its new Noida facility.
ஏன் இது முக்கியம்Noida reaching EBITDA profitability faster reduces initial drag on consolidated numbers, while Cluster 2 hospitals (Lucknow, Patna, Noida) delivered 110% YoY EBITDA growth, driving significant operating leverage.
Q2 FY27 Revenue from operations: INR 14,690 millionQ2 FY27 Operating EBITDA: INR 3,701 millionQ2 FY27 PAT: INR 2,191 millionGhaziabad land allotment value: INR 1,658.2 mnQuarterly Revenue vs TTM Revenue: ~31.4%
📅 குறுகிய காலம்Strong operational momentum with 60% EBITDA growth and bed additions should support investor sentiment around operating leverage.
📈 நீண்ட காலம்Capacity additions across Lucknow, Noida, and greenfield developments (Ghaziabad, Mumbai, Delhi, Guwahati) position the company for sustainable double-digit growth as mature and ramp-up clusters expand.
⚠ அபாய எச்சரிக்கைகள்
Depreciation and amortisation rose 42.4% YoY to INR 708 million, and finance costs grew 64.1% YoY to INR 281 million due to capital expansion
Execution risks across upcoming greenfield hospital projects
👀 கவனிக்க வேண்டியவை
Track the ongoing ramp-up and margin progression at the Noida hospital, alongside execution milestones for the greenfield pipelines including the newly allotted Ghaziabad land parcel.
Medanta Q2 FY27 PAT Jumps 38.3% to ₹219 Cr; Approves ₹997 Cr Ghaziabad Hospital
Global Health Limited (Medanta) reported strong Q2 FY27 results with revenue from operations growing 33.6% YoY to ₹1,469 crore and Operating EBITDA up 60.2% YoY to ₹370.1 crore. Operating EBITDA margins expanded 418 bps YoY to 25.2%, and Profit After Tax increased 38.3% YoY to ₹219.1 crore. Performance was driven by rapid ramp-up in its Noida hospital, which turned EBITDA positive (₹8.6 crore) within a year of launch. Alongside earnings, the Board approved a 500-bed greenfield hospital in Ghaziabad with an estimated capex of approximately ₹997 crore (~21% of TTM revenue).
உச்சம் நம்பிக்கை
என்ன மாறியதுMedanta reported Q2 FY27 financial results and formally announced Board approval for a new 500-bed hospital project in Ghaziabad with ₹997 crore capex.
ஏன் இது முக்கியம்Noida achieving quarterly EBITDA breakeven within 12 months removes a major operating drag, while the 500-bed Ghaziabad expansion brings their pipeline to over 3,450 greenfield beds, securing medium-term bed capacity growth.
📅 குறுகிய காலம்Strong operational momentum, margin expansion of 418 bps, and turnaround at Noida provide positive near-term operational clarity.
📈 நீண்ட காலம்With net cash of ₹781.5 crore, strong cash conversion (~86% EBITDA-to-cash flow), and a massive pipeline of over 3,450 greenfield beds across six projects, the growth runway remains solid.
⚠ அபாய எச்சரிக்கைகள்
Execution and delay risks across large multi-year greenfield hospital projects (Ghaziabad, Mumbai, Delhi, Guwahati).
Finance costs increased 64.1% YoY to ₹28.1 crore in Q2 FY27 as facilities scale.
👀 கவனிக்க வேண்டியவை
Monitor the construction and regulatory approval timeline for the newly approved Ghaziabad hospital, alongside continued occupancy ramp-up and margin sustainability at Noida.
Medanta Gurugram Hospital Director Dr. Pankaj Dhamija Resigns to Join Competition
Global Health Limited (Medanta) announced that Dr. Pankaj Dhamija, Hospital Director for its flagship Gurugram unit and a designated Senior Management Personnel, has resigned. He tendered his resignation on September 21, 2026, which was accepted on September 26, 2026. While his contractual notice ran until December 21, 2026, the company relieved him early on October 30, 2026, as he planned to join a competitor. The flagship Gurugram hospital remains central to Medanta's operations, where company-wide TTM revenue stands at Rs 4,683 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுDr. Pankaj Dhamija ceased to be Hospital Director of Medanta's Gurugram facility and a Senior Management Personnel effective October 30, 2026.
ஏன் இது முக்கியம்The Gurugram facility is Medanta's primary flagship hospital. While unit heads manage daily hospital operations, early relieving due to joining a competitor is noteworthy, though institutional doctor networks and group leadership typically mitigate operational disruptions.
Effective cessation date: அக்டோபர் 30, 2026Original contract end date: டிசம்பர் 21, 2026Resignation date: செப்டம்பர் 21, 2026Company TTM revenue context: Rs 4683 கோடி
📅 குறுகிய காலம்Limited operational impact expected as executive hospital administration transitions to interim leadership or an internal successor.
📈 நீண்ட காலம்Limited structural impact on the broader group given Medanta's established clinical governance and brand strength led by key doctors.
⚠ அபாய எச்சரிக்கைகள்
Departure to a competing healthcare provider from the core Gurugram operational unit
👀 கவனிக்க வேண்டியவை
Track the appointment of a successor for the Gurugram hospital leadership and monitor flagship facility operational stability in upcoming Q3 FY27 updates.
Medanta wins 10,560 sq m Ghaziabad land for ₹165.82 cr to build 350+ bed hospital
Global Health Limited (Medanta) has been allotted a 10,560 sq. metre freehold land parcel in Siddharth Vihar, Ghaziabad, via an online auction by UPAVP for approximately ₹165.82 crore. The site has the potential to house a 350+ bed hospital, subject to board and statutory approvals. The land acquisition cost represents ~4.1% of Medanta's net worth (₹4,013 crore) and ~3.5% of TTM revenue (₹4,683 crore). The proposed facility will complement Medanta's operational Noida facility and expand its NCR network across western Uttar Pradesh.
உச்சம் நம்பிக்கை
என்ன மாறியதுMedanta acquired a 10,560 sq. metre land parcel in Ghaziabad for ₹165.82 crore to set up a new hospital.
ஏன் இது முக்கியம்Adds potential capacity of 350+ beds in the Delhi-NCR cluster, strengthening Medanta's regional density and long-term bed pipeline.
Land acquisition cost: ₹165.82 கோடிLand area: 10,560 sq. metresProposed bed capacity: 350+ beddedLand cost vs Net worth: ~4.1%Current installed beds (as of June 30, 2026): 3,737
📅 குறுகிய காலம்Sentimentally positive as Medanta secures strategic land in high-demand Delhi-NCR; no immediate impact on earnings as construction is yet to begin.
📈 நீண்ட காலம்Supports sustained double-digit growth by deepening presence in western UP/NCR, acting as a feeder to core tertiary centers once operational over the next 3-4 years.
⚠ அபாய எச்சரிக்கைகள்
Execution risks and construction delays typical of greenfield hospital projects
Pending approvals from the Company's Board of Directors and statutory authorities
👀 கவனிக்க வேண்டியவை
Track board approval for hospital construction capex, environmental/statutory clearances, and guidance on the construction timeline and commissioning date.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Medanta Q1 FY27: 26% Revenue Growth to ₹1,326 Cr; Noida EBITDA Loss Shrinks to ₹4.9 Cr
Medanta (Global Health) delivered a strong Q1 FY27 with revenue growing 26% YoY to ₹1,326.2 Cr, supported by a 28% surge in inpatient volumes. While reported PAT of ₹157.3 Cr was slightly lower YoY due to a ₹19.6 Cr one-time gain in the base quarter, operational EBITDA grew 23% to ₹315.3 Cr. A key highlight is the Noida facility, which saw its EBITDA loss narrow significantly to ₹4.9 Cr from ₹23.6 Cr in the previous quarter, signaling an earlier-than-expected breakeven.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Noida facility has ramped up significantly faster than expected, and the Guwahati project has been upsized to 650 beds.
ஏன் இது முக்கியம்Faster turnaround of new hospitals like Noida reduces margin drag, while the upsized Guwahati project indicates strong demand and aggressive growth intent in the Northeast.
👀 கவனிக்க வேண்டியவை
Monitor the Noida facility for EBITDA breakeven in the next 1-2 quarters and track the execution timeline of the 2,000-bed greenfield expansion in Mumbai and Delhi.
26% Revenue Growth in Q1 FY27; Medanta Noida EBITDA Loss Narrows to ‡4.9 Cr
Global Health (Medanta) delivered a robust Q1 FY27 with total income rising 26.2% YoY to ‡1,326.2 cr, driven by a 27.7% surge in inpatient volumes. While reported PAT saw a marginal 1.1% dip to ‡157.3 cr, this was primarily due to a ‡19.6 cr exceptional gain in the base year (Q1 FY26). A critical positive is the Noida facility's performance, where revenue reached ‡85.5 cr and EBITDA losses narrowed significantly to ‡4.9 cr from ‡23.6 cr in the preceding quarter. Operational efficiency remained high with ARPOB increasing 5.5% to ‡70,244 and Average Length of Stay (ALOS) improving to 2.87 days.
உச்சம் நம்பிக்கை
என்ன மாறியதுMedanta has demonstrated a significant operational turnaround at its Noida facility and maintained strong double-digit volume growth across its network.
ஏன் இது முக்கியம்The narrowing losses in Noida and robust volume growth validate the company's ability to scale new large-format hospitals while maintaining high realizations (ARPOB).
📅 குறுகிய காலம்The stock is likely to react positively to the strong volume growth and the near-breakeven status of the Noida hospital, which has been a drag on margins.
📈 நீண்ட காலம்Structural growth is supported by a clear 2,000-bed expansion pipeline and increasing contribution from high-margin international patients and pharmacy retail.
⚠ அபாய எச்சரிக்கைகள்
Gestation risks for upcoming greenfield projects in Mumbai and Delhi
Intense competition in the NCR region impacting occupancy
👀 கவனிக்க வேண்டியவை
Watch for the Noida facility to turn EBITDA positive in H1 FY27 and monitor the execution timeline of the 2,000-bed greenfield expansion across Mumbai, Delhi, and Guwahati.
Medanta Q1 Revenue Up 22%; Guwahati Hospital Capacity Expanded to 650 Beds (Rs 970 Cr Capex)
Global Health Limited (Medanta) reported a 22.3% YoY increase in standalone revenue to Rs 1,078.72 cr for Q1 FY27. While standalone PAT declined 9.6% to Rs 137.31 cr, this was primarily due to a high base in the previous year which included an exceptional gain. A major highlight is the upward revision of the Guwahati hospital project from 400 to 650 beds, involving a total investment of Rs 970 cr. The company also fixed August 14, 2026, as the record date for a Rs 0.50 per share final dividend.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe planned Guwahati hospital project has been significantly upsized from 400 to 650 beds due to revised building bye-laws and increased FSI.
ஏன் இது முக்கியம்The Rs 970 cr investment in Guwahati is a major expansion that will add approximately 17% to the company's current total bed capacity, targeting a high-demand region with limited tertiary care.
Q1 Standalone Revenue: Rs 1,078.72 கோடிGuwahati Project Capex: Rs 970 கோடிCapex vs Net Worth: 24.17%Revised Guwahati Bed Capacity: 650 bedsDividend per share: Rs 0.50
📅 குறுகிய காலம்The strong revenue growth and significant expansion announcement are likely to be viewed positively by the market in the coming weeks.
📈 நீண்ட காலம்The expansion into Guwahati and Noida, totaling over 2,000 planned beds, aligns with the company's 15% growth strategy and strengthens its tertiary care leadership.
⚠ அபாய எச்சரிக்கைகள்
Execution risk over the 3-4 year construction timeline
Potential margin pressure during the gestation period of new large-scale facilities
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of the Guwahati project over the next 3-4 years and the ramp-up of the recently acquired Indore oncology facility.
Medanta Receives LOI for 150-Seat Medical College in Gurugram
Global Health Limited (Medanta) has received a Letter of Intent (LOI) from the Government of Haryana to establish a medical college at its flagship Gurugram facility. The college is sanctioned for 150 MBBS seats, marking the company's strategic entry into medical education. This initiative is designed to create a captive pipeline of high-quality clinical talent and strengthen the company's research and academic ecosystem. The development follows an earlier application made in March 2026, signaling a successful regulatory milestone.
முக்கிய அம்சங்கள்
Received Letter of Intent (LOI) from the Medical Education & Research Department, Government of Haryana.Approved for the establishment of a medical college with 150 MBBS seats.Project to be located at Medanta – The Medicity, Sector-38, Gurugram.Strategic move to ensure a continuous supply of trained clinical talent for the hospital chain.Follows up on the company's initial application dated March 25, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive long-term strategic move that enhances Medanta's brand value and talent retention; monitor for future disclosures regarding capital expenditure and construction timelines.
Medanta FY26 Revenue Up 20% to ₹45,089 Mn; Plans ₹45,000 Mn Capex for 2,700 New Beds
Global Health (Medanta) reported a strong 20% YoY growth in total income to INR 45,089 million for FY26, with PAT rising 15.1% to INR 5,541 million. The company is aggressively expanding, with a planned capex of INR 45,000 million over five years to add approximately 2,700 beds across five greenfield projects. Operational efficiency improved as ARPOB grew 6.1% to INR 66,550 and ALOS reduced to 3.04 days. While the new Noida facility impacted overall margins with an EBITDA loss of INR 783 million, quarterly losses are narrowing as the hospital ramps up.
முக்கிய அம்சங்கள்
Total income grew 20% YoY to INR 45,089 million, while PAT increased 15.1% to INR 5,541 million.ARPOB increased by 6.1% to INR 66,550, supported by a 4% improvement in Average Length of Stay (ALOS) to 3.04 days.Announced a massive expansion pipeline of 2,700 beds via 5 greenfield projects with a total capex of INR 45,000 million over 5 years.International patient revenue grew by 33% YoY, now contributing 7% to the total revenue mix.Board recommended a final dividend of INR 0.50 per share (25% of face value).
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to maintain high ARPOB and occupancy as it scales; the aggressive expansion plan signals strong long-term growth potential despite short-term margin pressure from new units.
Medanta FY26 Revenue Grows 20% to ₹4,509 Cr; EBITDA ex-Noida Up 19%
Global Health Limited (Medanta) reported a strong FY26 with total income rising 19.6% YoY to INR 45,089 million and PAT increasing 15.1% to INR 5,541 million. The company significantly expanded its capacity by adding 623 beds (20.5% growth), including the full operationalization of the 382-bed Noida facility. While the Noida unit reported an EBITDA loss of INR 783 million, startup losses are on a declining trend, and matured hospitals maintained steady growth. Operational metrics remained robust with a 16% increase in in-patient volumes and a 6.1% rise in ARPOB to INR 66,550.
முக்கிய அம்சங்கள்
Consolidated Total Income grew 19.6% YoY to INR 45,089 million in FY26EBITDA (excluding Noida) rose 18.6% to INR 11,343 million with a 25.7% marginTotal bed capacity increased by 20.5% with 623 additions, including 382 beds at the new Noida facilityIn-patient and Out-patient volumes grew by 16.0% and 18.7% respectively, while ARPOB reached INR 66,550Board recommended a final dividend of 25% on face value, amounting to INR 0.50 per share
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong volume growth and aggressive capacity expansion across Noida, Patna, and upcoming projects in Guwahati and Varanasi. The stock remains a high-conviction play in the healthcare sector as new units move toward profitability and matured units maintain high margins.
Medanta FY26 PAT Up 15.1% to INR 5,541M; Q4 PAT Surges 39.7% with Strong Bed Expansion
Global Health (Medanta) reported a strong FY26 with total income rising 19.6% to INR 45,089 million and PAT growing 15.1% to INR 5,541 million. The fourth quarter was particularly robust, with PAT jumping 39.7% y-o-y to INR 1,417 million, driven by higher patient volumes and improved realizations. The company successfully operationalized its 382-bed Noida facility, which is seeing narrowing EBITDA losses, and added a total of 623 beds across its network during the year. Management has recommended a dividend of INR 0.50 per share and outlined an aggressive expansion plan to add approximately 2,700 beds over the next 3-4 years.
முக்கிய அம்சங்கள்
FY26 Total Income grew 19.6% y-o-y to INR 45,089 million; Q4 Income hit record INR 11,958 millionFull-year PAT increased 15.1% to INR 5,541 million, while Q4 PAT surged 39.7% to INR 1,417 millionOperationalized 382 beds in Noida; total bed capacity increased by 20.5% y-o-y with 623 new beds added in FY26ARPOB grew 6.1% y-o-y to INR 66,550, and International Patient Revenue rose 33.2% to INR 2,780 millionAggressive expansion roadmap with ~3,200 total beds planned over the next 4 years across multiple cities including Mumbai and Delhi
👀 கவனிக்க வேண்டியவை
Investors should view the narrowing losses at the Noida facility and the massive 2,700-bed expansion pipeline as significant long-term growth catalysts. The strong Q4 performance and healthy ARPOB growth suggest the company is effectively scaling its high-margin tertiary care model.
Medanta FY26 Standalone Net Profit Rises to ₹4,962 Million; Proposes ₹0.50 Final Dividend
Global Health Limited (Medanta) reported a robust performance for the fiscal year ended March 31, 2026, with standalone revenue from operations growing 15.8% YoY to ₹37,093.78 million. The company's standalone net profit for the full year increased to ₹4,962.01 million, up from ₹4,615.28 million in the previous fiscal. The Board has recommended a final dividend of ₹0.50 per equity share (25% of face value). Additionally, the company announced key leadership changes, including the appointment of a new Chief Marketing & Growth Officer.
முக்கிய அம்சங்கள்
Standalone Revenue from operations for Q4 FY26 grew 19.6% YoY to ₹9,606.29 million.Full-year FY26 Standalone Net Profit increased to ₹4,962.01 million compared to ₹4,615.28 million in FY25.Board recommended a final dividend of ₹0.50 per equity share of face value ₹2 each.Total Standalone Income for FY26 rose to ₹38,157.86 million from ₹32,949.55 million in the previous year.Appointment of Kedar Ashok Apte as Chief Marketing & Growth Officer to drive expansion.
👀 கவனிக்க வேண்டியவை
Investors should take note of the steady double-digit revenue growth and the company's ability to maintain profitability despite rising employee costs. The stock remains a strong long-term play in the Indian healthcare sector given its brand equity and expansion focus.
Medanta FY26 Revenue Up 15.8% to ₹37,094 Mn; Announces ₹0.50 Dividend & Management Changes
Global Health Limited (Medanta) reported a steady financial performance for FY26, with annual revenue from operations growing 15.8% year-on-year to ₹37,093.78 million. Net profit for the full year increased to ₹4,962.01 million from ₹4,615.28 million in the previous fiscal year. The board has recommended a final dividend of ₹0.50 per equity share (25% of face value). Additionally, the company announced key leadership changes, including the appointment of a new Chief Marketing & Growth Officer and General Counsel to drive future expansion.
முக்கிய அம்சங்கள்
Annual Revenue from operations increased 15.8% YoY to ₹37,093.78 million in FY26Net Profit for FY26 rose to ₹4,962.01 million compared to ₹4,615.28 million in FY25Recommended a final dividend of ₹0.50 per equity share of face value ₹2 eachAppointed Kedar Ashok Apte as Chief Marketing & Growth Officer and Jagdeep Singh as General CounselQ4 FY26 revenue stood at ₹9,606.29 million, up from ₹8,028.68 million in the same quarter last year
👀 கவனிக்க வேண்டியவை
Investors should take note of the consistent double-digit revenue growth and the dividend payout as a sign of financial health. Monitor how the new leadership in marketing and growth impacts the company's expansion strategy in the coming quarters.
Medanta FY26 Results: PAT Grows to ₹496 Cr; Final Dividend of ₹0.50 Recommended
Global Health Limited (Medanta) reported a 15.8% year-on-year growth in annual revenue, reaching ₹37,093.78 million for FY26. Net profit for the full year increased to ₹4,962.01 million compared to ₹4,615.28 million in the previous fiscal year. The Board has recommended a final dividend of ₹0.50 per equity share (25% of face value). Additionally, the company announced key leadership changes, including the appointment of a new Chief Marketing & Growth Officer and General Counsel.
முக்கிய அம்சங்கள்
Annual Revenue from operations grew 15.8% YoY to ₹37,093.78 million.Net Profit (PAT) for FY26 increased to ₹4,962.01 million from ₹4,615.28 million in FY25.Board recommended a final dividend of ₹0.50 per equity share of face value ₹2.Q4 FY26 revenue stood at ₹9,606.29 million, up from ₹8,028.68 million in the same quarter last year.Appointed Kedar Ashok Apte as Chief Marketing & Growth Officer and Jagdeep Singh as General Counsel.
👀 கவனிக்க வேண்டியவை
The steady growth in revenue and profitability confirms Medanta's strong market position; investors should hold for long-term healthcare sector exposure while monitoring the impact of new leadership on growth initiatives.
Global Health (Medanta) to Host Q4 FY2026 Earnings Call on May 15, 2026
Global Health Limited (Medanta) has scheduled its earnings conference call for the fourth quarter and full year ended March 31, 2026, on May 15, 2026. The call will be led by top management, including CMD Dr. Naresh Trehan and CEO Pankaj Sahni, to discuss financial performance and growth outlook. As of December 31, 2025, the company maintained 3,579 installed beds across six operational hospitals. Investors will be looking for updates on the five upcoming hospital projects in Mumbai, Guwahati, Varanasi, and Delhi.
முக்கிய அம்சங்கள்
Earnings conference call scheduled for May 15, 2026, at 2:00 PM IST.Company operated 3,579 installed beds across 6 hospitals as of December 31, 2025.Five upcoming hospitals currently in the pipeline for Mumbai, Guwahati, Varanasi, and Delhi.Management team including CMD, CEO, and CFO will participate in the briefing.The call is hosted by ICICI Securities to discuss Q4 and FY2026 annual results.
👀 கவனிக்க வேண்டியவை
Investors should attend the call to gain insights into the occupancy levels of existing hospitals and the specific commissioning timelines for the five new projects. Focus on management's guidance regarding ARPOB (Average Revenue Per Occupied Bed) and expansion margins.
Medanta to Acquire 80-Bed Cancer Hospital in Indore for Rs 30 Crore
Global Health Limited (Medanta) has signed a Business Transfer Agreement to take over an 80-bed cancer hospital in Indore for a consideration of Rs 30 crore. The facility is strategically located just 500 meters from Medanta's existing 175-bed multi-specialty hospital, allowing for significant operational synergies. This acquisition enables Medanta to launch a comprehensive oncology program in Indore, filling a previous gap in its specialty offerings. The move strengthens the company's footprint in Central India and is expected to optimize capacity utilization across its Indore campus.
முக்கிய அம்சங்கள்
Acquisition of an 80-bed newly-built Cancer Care Hospital in Indore for Rs 30 croreFacility is located 500 meters from the existing 175-bed Medanta Indore hospitalAcquisition includes the transfer of business as a going concern and assignment of a long-term leaseEnables the launch of a comprehensive oncology program to enhance high-margin specialty offeringsMedanta's total operational network reached 3,579 installed beds as of December 31, 2025
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic, low-cost expansion that enhances Medanta's service mix and regional market share. Monitor the impact on Average Revenue Per Occupied Bed (ARPOB) as the high-margin oncology services scale up.
Medanta to Expand in UP with 400-Bed Varanasi Hospital and Rs 322 Cr Medical College
Global Health Limited (Medanta) has announced a significant expansion in Uttar Pradesh with a new 400-bed multi-specialty hospital in Varanasi. The project will follow a build-to-suit lease model where Medanta invests approximately Rs. 550 crores in medical equipment and interiors, while a partner develops the civil structure. Additionally, the company will invest Rs. 322 crores to establish a medical college directly under its corporate entity, leveraging revised NMC regulations. These projects, expected to be completed within four years, will strengthen Medanta's presence in the underserved Eastern UP market.
முக்கிய அம்சங்கள்
Planned 400-bed multi-specialty hospital in Varanasi with an estimated investment of Rs. 550 crores by Medanta.Approval for a new medical college with a project cost of Rs. 322 crores to be funded via internal accruals or debt.Varanasi project to be executed via a lease agreement with Shripal Hospitality, reducing initial civil construction capex.Total bed capacity in Uttar Pradesh to reach approximately 1,900 beds across Lucknow, Noida, and Varanasi.Project completion for the Varanasi hospital is targeted within a 4-year timeframe.
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this expansion as it targets a high-demand, underserved region using a capital-efficient lease model for the hospital building. Monitor the company's debt-to-equity ratio as it undertakes a combined investment of over Rs. 870 crores for these new ventures.
Medanta Shareholders Approve Key Director Appointments with Over 99% Majority
Global Health Limited (Medanta) has successfully passed three resolutions via postal ballot with overwhelming shareholder support. Dr. Ravi Gupta and Mr. Rajan Bharti Mittal were re-appointed as Independent Directors, receiving 99.64% and 99.65% of votes in favor, respectively. Furthermore, Ms. Shonan Purie Trehan was appointed as a Non-Executive Non-Independent Director with 99.82% approval. The high participation and near-unanimous voting from institutional and public shareholders reflect strong confidence in the company's governance.
முக்கிய அம்சங்கள்
Resolution for Dr. Ravi Gupta's re-appointment passed with 99.6383% votes in favor.Mr. Rajan Bharti Mittal's re-appointment as Independent Director secured 99.6517% approval.Appointment of Ms. Shonan Purie Trehan as Non-Executive Director passed with 99.8236% support.Total valid votes cast amounted to 24,12,94,677, representing high shareholder engagement across promoter and public categories.
👀 கவனிக்க வேண்டியவை
The overwhelming support for these appointments indicates strong institutional trust in Medanta's leadership. Investors can remain confident in the company's stable governance and continuity of its strategic direction.
Global Health Limited (Medanta) reported a robust 19% YoY revenue growth to Rs 11,428 million for Q3 FY26, driven by strong performance across its hospital network. While core EBITDA margins (excluding Noida) remained healthy at 25.4%, consolidated margins were pressured to 21.8% due to a Rs 320 million operating loss from the newly commissioned Noida facility. Reported PAT of Rs 950 million was impacted by a one-time exceptional labor code charge of Rs 366 million, though adjusted PAT stood higher at Rs 1,224 million. Operational metrics remained strong with ARPOB increasing 10% YoY to Rs 67,361.
முக்கிய அம்சங்கள்
Total income rose 19% YoY to Rs 11,428 million; Adjusted PAT stood at Rs 1,224 million excluding one-time items.ARPOB increased by 10% YoY to Rs 67,361, while Average Length of Stay (ALOS) improved by 7% to 3.02 days.International patient revenue grew significantly by 30% YoY to Rs 703 million.Noida facility completed its first full quarter with Rs 343 million revenue and expanded to 328 beds.Developing hospitals (Lucknow and Patna) delivered 22% revenue growth with strong EBITDA margins of 31.7%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the pace of the Noida facility's EBITDA breakeven and the execution of the 496-bed brownfield expansion pipeline. The stock remains a solid play on premium healthcare, but short-term margins will be influenced by the gestation period of new units.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
